Photodynamic theranostics in surgical treatment of patients with peritoneal carcinomatosis

Abstract

The role and possibilities of photodynamic theranostics, including fluorescence diagnostics and photodynamic therapy, in complex cytoreductive surgical treatment of peritoneal carcinomatosis, evaluation of the effectiveness of its use, and analysis of the impact of this approach on the results of surgical intervention were investigated. Available modern domestic and foreign scientific literature were analyzed using PubMed, eLibrary.ru, and Google Scholar. Peritoneal carcinomatosis is characterized by the spread of tumor cells in the peritoneum and can be either a primary form of a tumor, such as pseudomyxoma and mesothelioma, or metastatic spread of cancer, most often of the gastrointestinal tract or gynecological organs. Surgical treatment of peritoneal carcinomatosis is crucial in the complex treatment of this category of patients, which determines the importance of further improvement of cytoreductive technologies. The extent of peritoneal dissemination during surgery may be underestimated, since intraoperative diagnosis is based solely on visual inspection and palpation. Thus, the use of phototheranostics — fluorescence diagnostics and photodynamic therapy — is a promising direction that has an antitumor effect and visualizes the peritoneum involved in the oncological process, which is beneficial for determining the required volume of peritonectomy. Currently, they are promising methods in the treatment of tumors of various locations. Both techniques are linked by the principle of theranostics (including diagnosis of the disease and personalized treatment of the patient) and imply the use of specific dyes (photosensitizers) and their ability to be excited under the influence of light of a certain wavelength. The therapeutic and diagnostic potential of phototheranostics in the complex surgical treatment of peritoneal carcinomatosis is emphasized; the main problems are described and prospects for the development of this technology are presented based on retrospective and prospective studies and systematic reviews.

Keywords

peritoneal carcinomatosis / peritoneal carcinomatosis / fluorescent diagnostics / photodynamic therapy / peritonectomy / cytoreductive surgery / theranostics / phototheranostics / intraoperative diagnostics

References

[1] Xu S, Bulin AL, Hurbin A, et al. Photodynamic diagnosis and therapy for peritoneal carcinomatosis: Emerging perspectives. Cancers. 2020;12(9):24–91. doi: 10.3390/cancers12092491

[2] Xu S., Bulin A.L., Hurbin A., et al. Photodynamic diagnosis and therapy for peritoneal carcinomatosis: Emerging perspectives // Cancers. 2020. Vol. 12, N. 9. P. 24–91. doi: 10.3390/cancers12092491

[3] Flanagan M, Solon J, Chang KH, et al. Peritoneal metastases from extra-abdominal cancer — A population-based study. Eur J Surg Oncol. 2018;44(11):1811–1817. doi: 10.1016/j.ejso.2018.07.049

[4] Flanagan M., Solon J., Chang K.H., et al. Peritoneal metastases from extra-abdominal cancer — A population-based study // Eur J Surg Oncol. 2018. Vol. 44, N. 11. P. 1811–1817. doi: 10.1016/j.ejso.2018.07.049

[5] Kaprin AD, Starinsky VV, Shakhzadova AO, editors. The state of oncological care to the population of Russia in 2021. Moscow: P.A. Herzen Moscow State Medical Research Institute − branch of the Federal State Budgetary Institution “NMIC of Radiology”; 2022. 239 р. (In Russ.)

[6] Состояние онкологической помощи населению России в 2021 году / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 c.

[7] Vassos N, Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49. doi: 10.1007/s11864-018-0563-8

[8] Vassos N., Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options // Curr Treat Options Oncol. 2018. Vol. 19, N. 10. P. 49. doi: 10.1007/s11864-018-0563-8

[9] Breuer E, Hebeisen M, Schneider MA, et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis. J Natl Cancer Inst. 2021;113(8):1027–1035. doi: 10.1093/jnci/djab001

[10] Breuer E., Hebeisen M., Schneider M. A., et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis // J Natl Cancer Inst. 2021. Vol. 113, N. 8. P. 1027–1035. doi: 10.1093/jnci/djab001

[11] Solodkiy VA, Fomin DK, Goncharov SV, Kukushkina SA. Modern approaches to the treatment of peritoneal carcinomatosis from gastric cancer (literature review). Siberian Journal of Oncology. 2022;21(1):122–129. EDN: WPIKU doi: 10.21294/1814-4861-2022-21-1-122-129

[12] Солодкий В.А., Фомин Д.К., Гончаров С.В., Кукушкина С.А. Современные подходы к лечению перитонеального канцероматоза при раке желудка (обзор литературы) // Сибирский онкологический журнал. 2022. Т. 21, № 1. С. 122–129. EDN: WPIKU doi: 10.21294/1814-4861-2022-21-1-122-129

[13] Coccolini F, Gheza F, Lotti M, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979–6994. doi: 10.3748/wjg.v19.i41.6979

[14] Coccolini F., Gheza F., Lotti M., et al. Peritoneal carcinomatosis // World J Gastroenterol. 2013. Vol. 19, N. 41. P. 6979–6994. doi: 10.3748/wjg.v19.i41.6979

[15] Kitai T. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. Surg Today. 2021;51(7):1085–1098. doi: 10.1007/s00595-020-02180-7

[16] Kitai T. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan // Surg Today. 2021. Vol. 51, N. 7. P. 1085–1098. doi: 10.1007/s00595-020-02180-7

[17] Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–1064. doi: 10.2353/ajpath.2010.100105

[18] Lengyel E. Ovarian cancer development and metastasis // Am J Pathol. 2010. Vol. 177, N. 3. P. 1053–1064. doi: 10.2353/ajpath.2010.100105

[19] Azaïs H, Estevez JP, Foucher P, et al. Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge. Surg Oncology. 2017;26(1):46–52. doi: 10.1016/j.suronc.2017.01.001

[20] Azaïs H., Estevez J.P., Foucher P., et al. Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge // Surg Oncology. 2017. Vol. 26, N. 1. P. 46–52. doi: 10.1016/j.suronc.2017.01.001

[21] Nguyen VT, Prosvetov VA, Bromberg BB, et al. The possibility of using of cytoreductive technologies in the surgical treatment of patients with complicated disseminated tumors of the abdominal cavity and pelvic cavity. Bulletin of Pirogov National Medical and Surgical Center. 2023;18(1):74–80. EDN: UTPVTV doi: 10.25881/20728255_2023_18_1_74

[22] Нгуен В.Т., Просветов В.А., Бромберг Б.Б., и др. Возможность применения циторедуктивных технологий в хирургическом лечении больных с диссеминированными опухолями брюшной полости и малого таза // Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2023. Т. 18, № 1. С. 74–80. EDN: UTPVTV doi: 10.25881/20728255_2023_18_1_74

[23] Spiliotis J, Kopanakis N, Prodromidou A, et al. Peritoneal sarcomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surg Innov. 2021;28(3):394–395. doi: 10.1177/1553350620958259

[24] Spiliotis J., Kopanakis N., Prodromidou A., et al. Peritoneal sarcomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy // Surg Innov. 2021. Vol. 28, N. 3. P. 394–395. doi: 10.1177/1553350620958259

[25] Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10(1):3–23. doi: 10.1007/s13193-018-0856-1

[26] Sugarbaker P.H. Prevention and treatment of peritoneal metastases: a comprehensive review // Indian J Surg Oncol. 2019. Vol. 10, N. 1. P. 3–23. doi: 10.1007/s13193-018-0856-1

[27] Yonemura Y, Endou Y, Sasaki T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36(12):1131–1138. doi: 10.1016/j.ejso.2010.09.006

[28] Yonemura Y., Endou Y., Sasaki T., et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer // Eur J Surg Oncol. 2010. Vol. 36, N. 12. P. 1131–1138. doi: 10.1016/j.ejso.2010.09.006

[29] Glockzin G, Zeman F, Croner RS, et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 combatac trial. Clin Colorectal Cancer. 2018;17(4):285–296. doi: 10.1016/j.clcc.2018.07.011

[30] Glockzin G., Zeman F., Croner R.S., et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 combatac trial // Clin Colorectal Cancer. 2018. Vol. 17, N. 4. P. 285–296. doi: 10.1016/j.clcc.2018.07.011

[31] Narasimhan V, Britto M, Pham T, et al. Evolution of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: 8-year single-institutional experience. Dis Colon Rectum. 2019;62(10):1195–1203. doi: 10.1097/dcr.0000000000001456

[32] Narasimhan V., Britto M., Pham T., et al. Evolution of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: 8-year single-institutional experience // Dis Colon Rectum. 2019. Vol. 62, N. 10. P. 1195–1203. doi: 10.1097/dcr.0000000000001456

[33] Quénet F, Elias D., Roca L., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–266. doi: 10.1016/s1470-2045(20)30599-4

[34] Quénet F., Elias D., Roca L., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial // Lancet Oncol. 2021. Vol. 22, N. 2. P. 256–266. doi: 10.1016/s1470-2045(20)30599-4

[35] Abboud K, André T, Brunel M, et al. Management of colorectal peritoneal metastases: Expert opinion. J Visc Surg. 2019;156(5): 377–379. doi: 10.1016/j.jviscsurg.2019.08.002

[36] Abboud K., André T., Brunel M., et al. Management of colorectal peritoneal metastases: Expert opinion // J Visc Surg. 2019. Vol. 156, N. 5. P. 377–379. doi: 10.1016/j.jviscsurg.2019.08.002

[37] Prosvetov VA, Surov DA, Gaivoronsky IV, Nguyen VT. Innovative technology of total parietal peritonectomy for peritoneal carcinomatosis. Russian Military Medical Academy Reports. 2022;41(2):143–149. EDN: WWHFDH doi: 10.17816/rmmar104695

[38] Просветов В.А., Суров Д.А., Гайворонский И.В., Нгуен В.Т. Инновационная технология тотальной париетальной перитонэктомии при карциноматозе брюшины // Известия Российской военно-медицинской академии. 2022. Т. 41, № 2. С. 143–149. EDN: WWHFDH doi: 10.17816/rmmar104695

[39] Kyang LS, Dewhurst SL, See VA, Alzahrani NA, Morris DL. Outcomes and prognostic factors of cytoreductive surgery and perioperative intraperitoneal chemotherapy in high-volume peritoneal carcinomatosis. Int J Hyperthermia. 2022;39(1): 1106–1114. doi: 10.1080/02656736.2022.2112625

[40] Kyang L.S., Dewhurst S.L., See V.A., et al. Outcomes and prognostic factors of cytoreductive surgery and perioperative intraperitoneal chemotherapy in high-volume peritoneal carcinomatosis // Int J Hyperthermia. 2022. Vol. 39, N. 1. P. 1106–1114. doi: 10.1080/02656736.2022.2112625

[41] Somashekhar SP, Ashwin KR, Yethadka R, et al. Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC. Pleura and Peritoneum. 2019;4(4):20190015. doi: 10.1515/pp-2019-0015

[42] Somashekhar S.P., Ashwin K.R., Yethadka R., et al. Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC // Pleura and Peritoneum. 2019. Vol. 4, N. 4. Р. 20190015. doi: 10.1515/pp-2019-0015

[43] Mercier F, Mohamed F, Cazauran JB, et al. An update of peritonectomy procedures used in cytoreductive surgery for peritoneal malignancy. Int J Hyperthermia. 2019;36(1):744–752. doi: 10.1080/02656736.2019.1635717

[44] Mercier F., Mohamed F., Cazauran J.B., et al. An update of peritonectomy procedures used in cytoreductive surgery for peritoneal malignancy // Int J Hyperthermia. 2019. Vol. 36, N. 1. P. 744–752. doi: 10.1080/02656736.2019.1635717

[45] Karadayi K, Bostanci ME, Mollaoglu MC, Karabacak U. Cytoreductive surgery and perioperative intraperitoneal chemotherapy experience in peritoneal carcinomatosis: single-center analysis of 180 cases. Int J Surg Oncol. 2021;2021:8851751. doi: 10.1155/2021/8851751

[46] Karadayi K, Bostanci M.E., Mollaoglu M.C., Karabacak U. Cytoreductive surgery and perioperative intraperitoneal chemotherapy experience in peritoneal carcinomatosis: single-center analysis of 180 cases // Int J Surg Oncol. 2021. Vol. 2021. P. 8851751. doi: 10.1155/2021/8851751

[47] Nguyen VT, Prosvetov SA, Bromberg BB, et al. Historical, pathogenetic and clinical aspects of peritonectomy in patients with peritoneal canceromatosis. Medline.ru. 2022;23(2):705–721. EDN: MKHCUY

[48] Нгуен В.Т., Просветов С.А., Бромберг Б.Б., и др. Исторические, патогенетические и клинические аспекты перитонэктомии у больных канцероматозом брюшины // Medline.ru. 2022. Т. 23, № 2. С. 705–721. EDN: MKHCUY

[49] Liberale G, Vankerckhove S, Caldon MG, et al. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: A pilot study. Ann Surg. 2016;264(6):1110–1115. doi: 10.1097/sla.0000000000001618

[50] Liberale G., Vankerckhove S., Caldon M.G., et al. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: A pilot study // Ann Surg. 2016. Vol. 264, N. 6. P. 1110–1115. doi: 10.1097/sla.0000000000001618

[51] Boogerd LSF, Hoogstins CES, Schaap DP, et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol. 2018;3(3):181–191. doi: 10.1016/s2468-1253(17)30395-3

[52] Boogerd L.S.F., Hoogstins C.E.S., Schaap D.P., et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study // Lancet Gastroenterol Hepatol. 2018. Vol. 3, N. 3. P. 181–191. doi: 10.1016/s2468-1253(17)30395-3

[53] Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374. doi: 10.1007/978-1-4613-1247-5_23

[54] Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis // Cancer Treat Res. 1996. Vol. 82. P. 359–374. doi: 10.1007/978-1-4613-1247-5_23

[55] Nguyen VT, Prosvetov VA, Bromberg BB, et al. Methods to increase the effectiveness of cytoreductive surgical interventions in patients with complicated disseminated tumors of the abdominal cavity and pelvis. Bulletin of the Russian Military Medical Academy. 2023;25(1):23–32. EDN: DDRMCJ doi: 10.17816/brmma120006

[56] Нгуен В.Т., Просветов В.А., Бромберг Б.Б., и др. Пути повышения эффективности циторедуктивных оперативных вмешательств у больных, страдающих осложненными диссеминированными опухолями брюшной полости и малого таза // Вестник Российской военно-медицинской академии. 2023. Т. 25, № 1. С. 23–32. EDN: DDRMCJ doi: 10.17816/brmma120006

[57] Nguyen VT, Bromberg BB, Novikova MV, et al. Using two-stage cytoreductive surgery in a patient with complicated progressive small intestinal cancer. Bulletin of Pirogov National Medical and Surgical Center. 2022;17(3):142–147. EDN: SLNKVX doi: 10.25881/20728255_2022_17_3_142

[58] Нгуен В.Т., Бромберг Б.Б., Новикова М.В., и др. Двухэтапная циторедуктивная хирургия при осложненном прогрессирующем раке тонкой кишки // Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2022. Т. 17, № 3. С. 142–147. EDN: SLNKVX doi: 10.25881/20728255_2022_17_3_142

[59] Markovich VA, Tuzikov SA, Rodionov EO, et al. Gastric cancer: modern approaches and prospects of treatment for peritoneal carcinomatosis (literature review). Siberian Journal of Oncology. 2021;20(6):104–113. EDN: OPHHFD doi: 10.21294/1814-4861-2021-20-6-104-113

[60] Маркович В.А., Тузиков С.А., Родионов Е.О., и др. Рак желудка: современные подходы и перспективы лечения при канцероматозе брюшины (литературный обзор) // Сибирский онкологический журнал. 2021. Т. 20, № 6. С. 104–113. EDN: OPHHFD doi: 10.21294/1814-4861-2021-20-6-104-113

[61] Sugarbaker PH. Peritonectomy procedures. Ann surg. 1995;221(1):29–42. doi: 10.1097/00000658-199501000-00004

[62] Sugarbaker P.H. Peritonectomy procedures // Ann Surg. 1995. Vol. 221, N. 1. P. 29–42. doi: 10.1097/00000658-199501000-00004

[63] Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: A controlled study. Ann Surg Oncol. 2012;19(5):1416–1424. doi: 10.1245/s10434-012-2237-2

[64] Baratti D., Kusamura S., Cabras AD., Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: A controlled study // Ann Surg Oncol. 2012. Vol. 19, N. 5. P. 1416–1424. doi: 10.1245/s10434-012-2237-2

[65] Somashekhar SP, Ashwin KR, Kumar R, et al. Comparison of outcomes following complete and selective parietal peritonectomy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: a study by indian society of peritoneal surface malignancies (ISPSM). Indian J Gynecol Oncol. 2018;16(4). doi: 10.1007/s40944-018-0241-6

[66] Somashekhar S., Ashwin K.R., Kumar R., et al. Comparison of outcomes following complete and selective parietal peritonectomy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: a study by indian society of peritoneal surface malignancies (ISPSM) // Indian J Gynecol Oncol. 2018. Vol. 16, N. 4. doi: 10.1007/s40944-018-0241-6

[67] Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93–96. doi: 10.1002/jso.20676

[68] Sugarbaker P.H. Peritoneum as the first-line of defense in carcinomatosis // J Surg Oncol. 2007. Vol. 95, N. 2. P. 93–96. doi: 10.1002/jso.20676

[69] Abramovich SG. Phototherapy. Irkutsk: SC RRS SB RAMS; 2014. 200 р. (In Russ.)

[70] Абрамович С.Г. Фототерапия. Иркутск: РИО ФГБУ «НЦРВХ» СО РАМН, 2014. 200 с.

[71] Sanarova EV, Lantsova AV, Dmitrieva MV, et al. Photodynamic therapy is a way to improve the selectivity and efficiency of the tumor treatment. Russian Journal of Biotherapy. 2014;13(3):109–118. (In Russ.) EDN: SZVDPR

[72] Санарова Е.В., Ланцова А.В., Дмитриева М.В., и др. Фотодинамическая терапия - способ повышения селективности и эффективности лечения опухолей // Российский биотерапевтический журнал. 2014. Т. 13, № 3. С. 109–118. EDN: SZVDPR

[73] Papayan GV, Akopov AL. Fluorescence diagnostics in the near infrared range: equipment, application. Journal of Optical Technology. 2016;83(9):33–42. EDN: WRLEEV

[74] Папаян Г.В., Акопов А.Л. Флуоресцентная диагностика в ближнем инфракрасном диапазоне: аппаратура, применение // Оптический журнал. 2016. Т. 83, № 9. С. 33–42. EDN: WRLEEV

[75] Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC. Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity. Biochim Biophys Acta Rev Cancer. 2019;1872(2):188308. doi: 10.1016/j.bbcan.2019.07.003

[76] Donohoe C., Senge M.O., Arnaut L.G., Gomes-da-Silva L.C. Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity // Biochim Biophys Acta Rev Cancer. 2019. Vol. 1872, N. 2. P. 188308. doi: 10.1016/j.bbcan.2019.07.003

[77] Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy — mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–1107. doi: 10.1016/j.biopha.2018.07.049

[78] Kwiatkowski S., Knap B., Przystupski D., et al. Photodynamic therapy — mechanisms, photosensitizers and combinations // Biomed Pharmacother. 2018. Vol. 106. P. 1098–1107. doi: 10.1016/j.biopha.2018.07.049

[79] Allison RR. Photodynamic therapy: Oncologic horizons. Future Oncol. 2014;10(1):123–142. doi: 10.2217/fon.13.176

[80] Allison R.R. Photodynamic therapy: Oncologic horizons // Future Oncol. 2014. Vol. 10, N. 1. P. 123–142. doi: 10.2217/fon.13.176

[81] Akopov AL, Kazakov NV, Rusanov AA, Karlson A. The mechanisms of photodynamic action for treating of cancer patients. Biomedical Photonics. 2015;4(2):9–16. EDN: UKTTID doi: 10.24931/2413-9432-2015-4-2-9-16

[82] Акопов А.Л., Казаков Н.В., Русанов А.А., Карлсон А. Механизмы фотодинамического воздействия при лечении онкологических больных // Biomedical Photonics. 2015. Т. 4, № 2. С. 9–16. EDN: UKTTID doi: 10.24931/2413-9432-2015-4-2-9-16

[83] Suleimanov EA, Khomyakov VM, Serova LG, et al. Intraoperative photodynamic therapy for metastatic peritoneal tumors. Research’n Practical Medicine Journal. 2016;3(3):59–67. EDN: WKUVGF doi: 10.17709/2409-2231-2016-3-3-6

[84] Сулейманов Э.А., Хомяков В.М., Серова Л.Г., и др. Интраоперационная фотодинамическая терапия при метастатическом поражении брюшины // Исследования и практика в медицине. 2016. Т. 3, № 3. С. 59–67. EDN: WKUVGF doi: 10.17709/2409-2231-2016-3-3-6

[85] Hahn SM, Fraker DL, Mick R, et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res. 2006;12(8):2517–2525. doi: 10.1158/1078-0432.ccr-05-1625

[86] Hahn S.M., Fraker D.L., Mick R., et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis // Clin Cancer Res. 2006. Vol. 12, N. 8. P. 2517–2525. doi: 10.1158/1078-0432.ccr-05-1625

[87] Petrovskaya NA, Vozmitel MA, Kharuzhyk SA, Istomin YuP. Multimodal treatment of peritoneal carcinomatosis in experiment. Oncological Journal. 2011;5(4):60–68. (In Russ.) EDN: RUPKWP

[88] Петровская Н.А., Возмитель М.А., Хоружик С.А., Истомин Ю.П. Мультимодальное лечение перитонеального канцероматоза в эксперименте // Онкологический журнал. 2011. Т. 5, № 4 (20). С. 60–68. EDN: RUPKWP

[89] Suleimanov EA. Intraoperatsionnaya fluorestsentnaya diagnostika i fotodinamicheskaya terapiya bol’nykh s pervichnymi i metastaticheskimi opukholyami bryushiny [dissertation]. Moscow; 2018. 48 р. (In Russ.)

[90] Сулейманов Э.А. Интраоперационная флуоресцентная диагностика и фотодинамическая терапия больных с первичными и метастатическими опухолями брюшины: автореф. дис. … д-ра мед. наук. Москва, 2018. 48 с.

[91] Krochek IV, Sergiyko SV, Ibatullin RD, Anchugova AE, Grekova NM. Combined treatment of local-regional cancer with replacement of intraoperative photodynamic therapies, first results. In: Topical issues of surgery: Collection of scientific and practical works. 2020;13:167–173. (In Russ.)

[92] Крочек И.В., Сергийко С.В., Ибатуллин Р.Д., и др. Комбинированное лечение местно-распространенного рака толстого кишечника с применением интраоперационной фотодинамической терапии, первые результаты // Актуальные вопросы хирургии: сборник научно-практических работ. 2020. Т. 13. С. 167–173.

[93] Popovkina OE, Kapinus VN, Yaroslavtseva-Isayeva EV, et al. Development of fluorescence diagnosis and photodynamic therapy in A. Tsyb Medical Radiological Research Centre. Radiation and risk. 2022;31(2):139–150. EDN: HWIMME doi: 10.21870/0131-3878-2022-31-2-139-150

[94] Поповкина О.Е., Капинус В.Н., Ярославцева-Исаева Е.В., и др. Развитие методов фотодинамической диагностики и терапии в МРНЦ им. А.Ф. Цыба // Радиация и риск. 2022. Т. 31, № 2. С. 139–150. EDN: HWIMME doi: 10.21870/0131-3878-2022-31-2-139-150

[95] Rizvi I, Celli JP, Evans CL, et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res. 2010;70(22):9319–9328. doi: 10.1158/0008-5472.can-10-1783

[96] Rizvi I., Celli J.P., Evans C.L., et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer // Cancer Res. 2010. Vol. 70, N. 22. P. 9319–9328. doi: 10.1158/0008-5472.can-10-1783

[97] Spring BQ, Abu-Yousif AO, Palanisami A, et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci USA. 2014;111(10):E933–E942. doi: 10.1073/pnas.1319493111

[98] Spring B.Q., Abu-Yousif A.O., Palanisami A., et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates // Proc Natl Acad Sci U S A. 2014. Vol. 111, N. 10. P. E933–E942. doi: 10.1073/pnas.1319493111

[99] Xin J, Wang S, Zhang L, et al. Comparison of the synergistic anticancer activity of AlPcS4 photodynamic therapy in combination with different low-dose chemotherapeutic agents on gastric cancer cells. Oncol Rep. 2018;40(1):165–178. doi: 10.3892/or.2018.6438

[100] Xin J., Wang S., Zhang L., et al. Comparison of the synergistic anticancer activity of AlPcS4 photodynamic therapy in combination with different low-dose chemotherapeutic agents on gastric cancer cells // Oncol Rep. 2018. Vol. 40, N. 1. P. 165–178. doi: 10.3892/or.2018.6438

[101] Korshunova OV, Plekhova NG. Photodynamic therapy in oncology: present and future. Pacific Medical Journal. 2020;4(82):15–19. EDN: ALTTRK doi: 10.34215/1609-1175-2020-4-15-19

[102] Коршунова О.В., Плехова Н.Г. Фотодинамическая терапия в онкологии: настоящее и будущее // Тихоокеанский медицинский журнал. 2020. № 4(82). С. 15–19. EDN: ALTTRK doi: 10.34215/1609-1175-2020-4-15-19

[103] Zakharenko AA, Natkha AS, Trushin AA, et al. Pressured itraperitoneal aerosol chemotherapy — a new effective way of treatment of implantation metastasises (Review). Medline.ru. 2015;16:834–849. EDN: ZEQGHV

[104] Захаренко А.А., Натха А.С., Трушин А.А., и др. Аэрозольная внутрибрюшинная химиотерапия — новый эффективный способ лечения канцероматоза брюшины (обзор литературы) // Medline.ru. 2015. Т. 16. С. 834–849. EDN: ZEQGHV

[105] Almyashev AZ. Modern laser information technologies in clinical oncology. Medicus. 2021;6(42):30–49. EDN: OCDXVX

[106] Альмяшев А.З. Современные лазерно-информационные технологии в клинической онкологии // Medicus. 2021. № 6 (42). С. 30–49. EDN: OCDXVX

[107] Riabov MV. Photodynamic therapy. Current state and prospects of development. In: Lasers in science, technology, medicine: Collection of scientific papers of the XXXI international conference. Moscow; 2020. Р. 178–182.

[108] Рябов М.В. Фотодинамическая терапия. Современное состояние и перспективы развития // Лазеры в науке, технике, медицине: сборник научных трудов XXXI Международной конференции. Москва, 2020. С. 178–182.

RIGHTS & PERMISSIONS

Eco-Vector